^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Avastin (bevacizumab) (VEGF-A inhibitor) + Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01.
Published date:
05/26/2022
Excerpt:
Women with PSR ovarian cancer who had a partial or complete response to their most recent platinum-based regimen were eligible. Patients received olaparib 300mg PO bid daily, bevacizumab 15mg/kg IV q3w, and pembrolizumab 200mg IV…Patients received olaparib 300mg PO bid daily, bevacizumab 15mg/kg IV q3w, and pembrolizumab 200mg IV...OPEB-01 is the first trial to suggest the potential benefit of triple combination maintenance in BRCA wild-type patients.
DOI:
10.1200/JCO.2022.40.16_suppl.e17579
Trial ID:
